Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.45 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978437 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL15010125 | 0.95 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15010684 | 0.95 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15010682 | 0.95 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15010121 | 0.95 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15010124 | 0.95 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL12068362 | 0.95 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL1236250 | 0.92 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL9898738 | 0.92 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 | |
| SCHEMBL9898742 | 0.92 | ALDH1A1 (0.54) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323548-A1 | NOVEL AMINO ALCOHOL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2014-10-30 | — | — | US | claimed |
| US-8802863-B2 | Amino alcohol cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2014-08-12 | — | — | US | claimed |
| US-20130150625-A1 | Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-06-13 | — | — | US | claimed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4414002-B1 | RAC2 G12V MUTANT FOR USE IN ABLATING HEMATOPOIESIS AND IN THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | INST NAT SANTE RECH MED (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260124295-A1 | USE OF LIPID NANOPARTICLES AND IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER | UNIV FLORIDA (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115326-A1 | LIPID NANOPARTICLES WITH RNA FOR COSMETIC TREATMENT | Lipovectra Inc. (US) | 2026-04-30 | — | — | US | disclosed |
| US-12611456-B2 | Use of thiazole amide compounds for modulating human immune response | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20140323548-A1 | NOVEL AMINO ALCOHOL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2014-10-30 | — | — | US | disclosed |
| US-8802863-B2 | Amino alcohol cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802863-B2 | Amino alcohol cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802863-B2 | Amino alcohol cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130150625-A1 | Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-06-13 | — | — | US | disclosed |
| US-20130150625-A1 | Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-06-13 | — | — | US | disclosed |
| US-20130150625-A1 | Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-06-13 | — | — | US | disclosed |
| EP-2575895-A2 | NOVEL AMINO ALCOHOL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | Merck Sharp & Dohme Corp. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011149733-A2 | NOVEL AMINO ALCOHOL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | ALDH1A1 4705/4885CNR1 3654/4885CNR2 4366/4885 |
| US-20130150625-A1 | Novel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery | CETP, SLC7A5, NPC1L1 | ALDH1A1 1428/4885CNR1 1768/4885CNR2 2399/4885 |
| US-20140323548-A1 | NOVEL AMINO ALCOHOL CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | CETP, SLC7A5, NPC1L1 | ALDH1A1 1428/4885CNR1 1768/4885CNR2 2399/4885 |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, METTL16, NSUN2 | ALDH1A1 4565/4885CNR1 2945/4885CNR2 4198/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | ALDH1A1 4802/4885CNR1 2667/4885CNR2 3277/4885 |
| US-20260115326-A1 | LIPID NANOPARTICLES WITH RNA FOR COSMETIC TREATMENT | FABP4, LIPC, ACADVL | ALDH1A1 2335/4885CNR1 3428/4885CNR2 3000/4885 |
| US-20260124295-A1 | USE OF LIPID NANOPARTICLES AND IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER | PDCD1, CD274, PDCD1LG2 | ALDH1A1 3233/4885CNR1 2760/4885CNR2 2108/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | ALDH1A1 4843/4885CNR1 4516/4885CNR2 4315/4885 |
| US-12611456-B2 | Use of thiazole amide compounds for modulating human immune response | NOD1, TLR1, HLA-DRB1 | ALDH1A1 1844/4885CNR1 563/4885CNR2 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.